Plant Name: Solanum lycopersicum
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| HTR2C; HTR1D; HTR1B; HTR2A; HTR6; | |
| CA2; CA1; CA9; CA5B; CA14; CA5A; CA4; CA6; CA7; | |
| ALOX5; PTGS2; | |
| MPO; IDO1; | |
| RAB9A; LMNA; NPC1; THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
| Enzyme_unclassified | IDO1 | Indoleamine 2,3-dioxygenase | P14902 | CHEMBL4685 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
| Small molecule receptor (family A GPCR) | HTR1D | Serotonin 1d (5-HT1d) receptor | P28221 | CHEMBL1983 |
| Small molecule receptor (family A GPCR) | HTR1B | Serotonin 1b (5-HT1b) receptor | P28222 | CHEMBL1898 |
| Small molecule receptor (family A GPCR) | HTR2A | Serotonin 2a (5-HT2a) receptor | P28223 | CHEMBL224 |
| Small molecule receptor (family A GPCR) | HTR6 | Serotonin 6 (5-HT6) receptor | P50406 | CHEMBL3371 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.659E-13 | 4.516E-10 | CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, IDO1, MPO, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 4.169E-12 | 8.837E-09 | CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 2.210E-10 | 2.406E-07 | HTR1B, HTR1D, HTR2A, HTR2C, HTR6 |
| MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 2.210E-10 | 2.406E-07 | HTR1B, HTR1D, HTR2A, HTR2C, HTR6 |
| MF | GO:0005488; binding | GO:0051378; serotonin binding | 1.342E-09 | 1.270E-06 | HTR1B, HTR1D, HTR2A, HTR2C |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.432E-09 | 1.299E-06 | CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.011E-09 | 1.751E-06 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.141E-09 | 2.358E-06 | ALOX5, CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.215E-09 | 4.366E-06 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.216E-08 | 7.564E-06 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.409E-08 | 1.311E-05 | CYP1A2, CYP2A6, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 6.305E-08 | 3.178E-05 | CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, NPC1 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.625E-07 | 1.594E-04 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 6.952E-07 | 2.752E-04 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 2.040E-06 | 7.051E-04 | CYP2A6, CYP2C19, CYP2C9 |
| BP | GO:0009987; cellular process | GO:0007208; phospholipase C-activating serotonin receptor signaling pathway | 2.176E-06 | 7.291E-04 | HTR2A, HTR2C |
| MF | GO:0005488; binding | GO:0071886; 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding | 2.176E-06 | 7.291E-04 | HTR2A, HTR2C |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 5.281E-06 | 1.691E-03 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 6.523E-06 | 2.029E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 6.523E-06 | 2.029E-03 | CA2, CA7 |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 7.830E-06 | 2.368E-03 | CA2, CA9, CYP1A2, HTR1B, IDO1, MPO, NPC1, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0016702; oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen | 7.729E-06 | 2.368E-03 | ALOX5, IDO1, PTGS2 |
| BP | Unclassified; | GO:0042310; vasoconstriction | 1.083E-05 | 3.187E-03 | HTR1B, HTR1D, HTR2A |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.857E-05 | 5.055E-03 | CA1, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0010513; positive regulation of phosphatidylinositol biosynthetic process | 2.170E-05 | 5.834E-03 | HTR2A, HTR2C |
| BP | GO:0050896; response to stimulus | GO:0042221; response to chemical | 2.319E-05 | 6.159E-03 | CA2, CA9, CYP1A2, HTR1B, HTR1D, HTR2A, HTR2C, IDO1, LMNA, MPO, NPC1, PTGS2, TSHR |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 3.252E-05 | 8.431E-03 | CA1, CA2 |
| BP | GO:0032501; multicellular organismal process | GO:0097746; regulation of blood vessel diameter | 3.393E-05 | 8.592E-03 | HTR1B, HTR1D, HTR2A, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.841E-23 | 1.054E-18 | CA1, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.674E-18 | 7.266E-14 | CA1, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.634E-16 | 1.434E-12 | CA1, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.178E-14 | 9.886E-11 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.716E-22 | 8.581E-21 | CA1; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.686E-16 | 9.214E-15 | CYP2C9; HTR6; CYP2D6; ALOX5; HTR1D; HTR1B; HTR2C; HTR2A; CYP2C19; PTGS2 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 6.024E-10 | 1.004E-08 | CYP2C9; CYP2A6; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.737E-09 | 2.172E-08 | CYP2C9; CYP2A6; CYP1A2; CYP3A4; CYP2C19; PTGS2 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 6.252E-08 | 6.252E-07 | CYP2C9; CYP2A6; CYP2D6; CYP1A2; CYP3A4 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.876E-06 | 1.340E-05 | CYP2C9; ALOX5; CYP2C19; PTGS2 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 8.255E-08 | 6.879E-07 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 2.430E-06 | 1.350E-05 | HTR6; HTR1D; HTR1B; HTR2C; HTR2A; TSHR |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.270E-06 | 1.350E-05 | CYP2C9; CYP2A6; CYP1A2; CYP3A4 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.859E-04 | 8.448E-04 | HTR6; HTR1D; HTR1B; TSHR |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.820E-04 | 1.175E-03 | CYP2C9; CYP2A6; ALOX5; CYP1A2; PTGS2; CYP2C19; CYP3A4; IDO1 |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 2.205E-03 | 6.892E-03 | HTR6; HTR2C; HTR2A |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.530E-03 | 5.465E-03 | CYP1A2; IDO1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.382E-03 | 7.005E-03 | ALOX5; PTGS2 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 2.978E-03 | 8.273E-03 | PTGS2; TSHR |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.020E-03 | 6.732E-03 | CYP2A6; CYP3A4 |
| hsa04742 | Taste transduction_Homo sapiens_hsa04742 | 6.424E-03 | 1.529E-02 | HTR1D; HTR1B |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 8.853E-03 | 1.925E-02 | HTR2C; HTR2A |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 3.191E-03 | 8.398E-03 | CYP1A2; CYP3A4 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 4.742E-03 | 1.185E-02 | CA2; CYP3A4 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 7.194E-03 | 1.635E-02 | HTR2C; HTR2A |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 5.040E-04 | 1.938E-03 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.025E-05 | 1.012E-04 | CYP2A6; CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | HTR1D |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO |
| C00-D49: Neoplasms | Cancer | C00-C96 | CA1; CA9; IDO1; PTGS2 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | HTR2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| NA: NA | Addiction | NA | HTR2A |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HTR2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep maintenance insomnia | F51.0, G47.0 | HTR2A |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | HTR6 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HTR2C |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; MPO |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS2; PTGS2; PTGS2; PTGS2 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | HTR2A |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; PTGS2; PTGS2 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PTGS2; PTGS2; PTGS2; PTGS2; HTR2C |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| NA: NA | Primary insomnia | NA | HTR2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | HTR2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | HTR1B; HTR2C |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; MPO; PTGS2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HTR2C; HTR2C; HTR6 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | HTR6 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; PTGS2 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HTR2C; HTR6 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Hemorrhoids | I84 | HTR2A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; PTGS2; PTGS2; PTGS2; PTGS2 |
| NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | HTR1D; HTR2A; CYP2D6 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | HTR1D; HTR1B; HTR2C |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2 |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | HTR6 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR2A; HTR2A; HTR2C; HTR6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | HTR2A; HTR2C |
| C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR1D; HTR1B; HTR2C; HTR2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Erythropoietic porphyria | E80.0 | HTR2A |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | HTR1D |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | HTR1D |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR2A |
| NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; HTR2A |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; HTR6; HTR6; HTR6 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR2C |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | HTR2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; HTR1B; HTR2A; HTR2C; HTR6; HTR6 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HTR2A; HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | HTR6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | IDO1; HTR2A; HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Chronic schizophrenics | F20 | HTR1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR1D; HTR1B; HTR2A; HTR2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HTR2A |